Commentary

Video

Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

Author(s):

David B. Zhen, MD,Samuel Cytryn, MD

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Related Videos
Neil Iyengar, MD, and Chandler Park, MD, FACP
Eytan M. Stein, MD
Eytan M. Stein, MD
Michael A. Postow, MD
Alison Schram, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Related Content
Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com
December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

FDA
December 18th 2024

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Renal Cell Carcinoma | stock.adobe.com
December 13th 2024

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

Michael J. Pishvaian, MD, PhD, director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, associate professor of Oncology, Johns Hopkins Medicine
December 13th 2024

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management